Randomized trial for prevention of post ERCP pancreatitis with celecox tablets

Randomized trial for prevention of post ERCP pancreatitis with celecox tablets - Randomized trial for prevention of post ERCP pancreatitis with celecox tablets

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012964

Enrollment

170

Registered

2014-01-27

Start date

2014-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post ERCP pancreatitis

Interventions

control group(Non-administration of celecox tablets) celecox tablets administered before ERCP group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are planned to perform ERCP for further evaluation or treatment. Written informed consent is obtained from patient before the study.

Exclusion criteria

Exclusion criteria: Patients who have severe heart disease, hepatic insufficiency, renal dysfunction, endocrine disease, or gastrointestinal tract disturbance. Patients with acute or chronic pancreatitis which need fasting therapy. Patients who take NSAIDs usually. Patients with a history of asthma of aspirin and allergia of iodine. Patients who performed operation of reconstraction for intestinal track by gastorectomy. Patients without informed consent. Patients who are judged inappropriate by chief (responsive) medical examiner.

Design outcomes

Primary

Measure	Time frame
The primary endpoints are frequency of post ERCP pancreatitis.	—

Countries

Japan

Contacts

Public ContactSatoshi Sugimori

Osaka City University Graduate School of Medicine Department of gastroenterological medicine

m1151329@med.osaka-cu.ac.jp06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026